FY2025 EPS Estimates for ADMA Biologics Lowered by Analyst

ADMA Biologics Inc (NASDAQ:ADMA - Free Report) - Analysts at Cantor Fitzgerald reduced their FY2025 EPS estimates for shares of ADMA Biologics in a research note issued to investors on Wednesday, June 25th. Cantor Fitzgerald analyst K. Kluska now expects that the biotechnology company will earn $0.61 per share for the year, down from their previous forecast of $0.72. Cantor Fitzgerald has a "Overweight" rating and a $25.00 price target on the stock. The consensus estimate for ADMA Biologics' current full-year earnings is $0.51 per share. Cantor Fitzgerald also issued estimates for ADMA Biologics' FY2026 earnings at $0.89 EPS.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). ADMA Biologics had a net margin of 45.01% and a return on equity of 47.16%. The firm had revenue of $114.80 million during the quarter, compared to the consensus estimate of $116.40 million. During the same quarter in the previous year, the company posted $0.08 earnings per share. The firm's revenue was up 40.2% on a year-over-year basis.

Several other research analysts also recently issued reports on ADMA. Raymond James Financial upped their price objective on ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research note on Thursday, May 8th. Wall Street Zen cut shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th.

ADMA Biologics Price Performance

ADMA Biologics stock opened at $17.60 on Thursday. The stock has a 50-day moving average price of $20.69 and a two-hundred day moving average price of $18.76. ADMA Biologics has a 12 month low of $10.21 and a 12 month high of $25.67. The company has a market capitalization of $4.20 billion, a PE ratio of 20.71 and a beta of 0.47. The company has a current ratio of 6.58, a quick ratio of 3.36 and a debt-to-equity ratio of 0.22.

Institutional Investors Weigh In On ADMA Biologics

A number of institutional investors have recently modified their holdings of the company. Raymond James Financial Inc. acquired a new position in ADMA Biologics in the fourth quarter valued at $19,076,000. JPMorgan Chase & Co. raised its position in shares of ADMA Biologics by 272.5% in the 4th quarter. JPMorgan Chase & Co. now owns 767,265 shares of the biotechnology company's stock worth $13,159,000 after acquiring an additional 561,310 shares in the last quarter. Victory Capital Management Inc. lifted its stake in shares of ADMA Biologics by 52.8% in the 4th quarter. Victory Capital Management Inc. now owns 109,948 shares of the biotechnology company's stock valued at $1,886,000 after purchasing an additional 38,002 shares during the period. Sei Investments Co. boosted its position in shares of ADMA Biologics by 147.2% during the 4th quarter. Sei Investments Co. now owns 527,272 shares of the biotechnology company's stock valued at $9,043,000 after purchasing an additional 314,013 shares in the last quarter. Finally, Swiss National Bank boosted its position in shares of ADMA Biologics by 6.6% during the 4th quarter. Swiss National Bank now owns 458,400 shares of the biotechnology company's stock valued at $7,862,000 after purchasing an additional 28,500 shares in the last quarter. 75.68% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, Director Steve Elms sold 194,749 shares of the firm's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the completion of the transaction, the director now directly owns 87,330 shares in the company, valued at $1,767,559.20. This trade represents a 69.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Lawrence P. Guiheen sold 7,779 shares of the company's stock in a transaction that occurred on Wednesday, May 21st. The shares were sold at an average price of $20.32, for a total value of $158,069.28. Following the completion of the sale, the director now owns 114,830 shares in the company, valued at $2,333,345.60. The trade was a 6.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 464,621 shares of company stock valued at $9,644,269. 3.50% of the stock is currently owned by company insiders.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.